Phase 2 N=40 Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions
Macular Edema · Retinal Vein Occlusion
Primary: Best Corrected Visual Acuity Change From Baseline at All Visits — 10.5; 15.1 ETDRS letters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Change in ETDRS Best Corrected Visual Acuity From Baseline at 54 Weeks — 14 ETDRS letters
N/A N=608 An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
Macular Edema · Retinal Vein Occlusion
Primary: Number of Participants With Ocular Adverse Events in the Study Eye — 51; 64; 63; 60 participants
Phase 3 N=668 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 53; 48; 38 Number of Participants
Phase 3 N=599 A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Cumulative Response Rate of 15 or More Letter Improvement — 0.101; 0.092; 0.045; 0.258 Kaplan-Meier Estimate
N/A N=323 A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
Retinal Vein Occlusion · Macular Edema
Primary: Percentage of Participants With Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence…
Phase 3 N=40 Ozurdex for Retinal Vein Occlusion Study (ORVO Study)
Retinal Vein Occlusion
Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants
Phase 3 N=66 Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion
Retinal Vein Occlusion
Primary: Incidence of Serious Adverse Events. — 17 number of serious adverse events
Phase 3 N=357 Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Macular Edema · Central Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) at Month 12 Compared to Baseline — 12.3 Letters
N/A N=375 Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 47.56; 5.09 Letters
N/A N=45 Combined Therapy of Posterior Subtenon Triamcinolone Acetonide and Intravitreal Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
Branch Retinal Vein Occlusion
Primary: Changes of Central Retinal Thickness — 510.35; 468.22; 291.48; 233.33 micrometer — p=0.60
Phase 4 N=71 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 6 — 51.90; 18.60 letters
Phase 2 N=14 Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
Branch Retinal Vein Occlusion · Central Retinal Vein Occlusion · Macular Edema
Primary: Mean Change From Baseline BCVA — 14; 5 Letters (ETDRS chart)
Phase 3 N=262 Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)
Macular Edema
Primary: Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye — 60; 31 Patients
N/A N=30 Comparison of Intravitreal Anti-VEGF Versus Combination Therapy in Central Retinal Vein Occlusion
Central Retinal Vein Occlusion With Macular Edema
Primary: Visual Acuity — 0.32; 0.44 logMAR units
Phase 4 N=31 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Phase 4 N=202 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion
Macular Edema
Primary: Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15 — 17.5; 19.7; 18.7; 21.0 Letters — p=0.5091
Phase 2 N=20 Diabetic Macular Edema Treated With Ozurdex (DMEO)
Diabetic Macular Edema
Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…
Phase 3 N=10 Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
Retinal Vein Occlusion · Macular Edema
Primary: Macular Function Using Microperimetry — 2.7; 12.7; 4.2; 10.7 dB
Phase 2 N=81 Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions
Retinal Vein Occlusion
Primary: Incidence and Severity of Ocular and Non-ocular Adverse Events. — 17; 12; 37; 35 participants
Phase 3 N=892 A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)
Macular Edema Secondary to Retinal Vein Occlusion
Primary: Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 36 — 17.5; 17.4; 18.3 Letters — p=<0.0001
Phase 3 N=189 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Macular Edema Secondary to Central Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score — 64; 9 percentage of participants — p=< 0.0001
Phase 3 N=177 Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Retinal Vein Occlusion
Primary: Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants…
Phase 2 N=49 Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Macular Edema
Primary: Safety Tolerability: Number of Ocular and Non-ocular TEAEs — 5; 22; 22 participants
Phase 4 N=162 Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Central Retinal Vein Occlusion
Primary: The Proportion of Participants Who Gained ≥ 15 Letters in Best Corrected Visual Acuity (BCVA) on the Early Treatment Diabetic Retinopathy Score (ETDRS) Chart Compared to…
Phase 2 N=302 Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema
Diabetic Macular Edema
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 6.8; 8.5; 8.8…
Phase 2 N=121 Safety and Efficacy of AGN208397 in the Treatment of Macular Edema Associated With Retinal Vein Occlusion (RVO)
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline at Month 1 in Retinal Thickness in the Study Eye During Stage 1 — 500.2; 495.8; 499.5; 468.3 Microns
N/A N=573 A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)
Macular Edema · Retinal Vein Occlusion
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye — 52.431; 7.774 Approximate EDTRS Letters
N/A N=30 A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
Central Retinal Vein Occlusion
Primary: Change From Baseline in Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS) Charts — 12.5; 14; 13.5 letters read correctly
Phase 4 N=30 Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections